Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A traditional Chinese medicine herbal mixture called Ren Shen Yangrong Tang (RSYRT) significantly reduced fatigue in cancer patients with moderate to severe symptoms. In a Phase I/II trial, RSYRT was found to be safe and effective in improving Qi deficiency, a key factor contributing to fatigue.
Researchers have designed a nanoparticle-based therapy that effectively treats mice with multiple myeloma, a cancer of immune cells in the bone marrow. The nanoparticles carry a Myc inhibitor, which blocks a protein active in many types of cancer, and increase survival by 23 days compared to control groups.
Researchers at University Hospitals Cleveland Medical Center found a new non-invasive stool DNA testing method comparable to colonoscopy for detecting large polyps in African Americans. The study suggests this technology may improve colon cancer screening rates and decrease mortality.
A study has quantified the different mutational profiles of cancer cells in individual tumors, revealing a high degree of variability within one tumor. The researchers found that certain genes behave differently in cancer cells, with some tumors composed of multiple groups with distinct molecular alterations.
Researchers at Oregon State University have developed pactamycin analogs that can cause rapid cell aging and induce premature senescence in cancer cells, slowing or stopping tumor growth. The findings show promise for a new approach to cancer treatment with reduced toxicity and debilitating side effects.
A study published in Annals of Internal Medicine suggests that women with extremely dense breasts do not necessarily need additional imaging after a normal mammogram. However, those with high-risk dense breasts should discuss supplemental screening strategies with their doctors. The American College of Physicians advises 'smarter' canc...
Researchers at the University of Birmingham have found a combination of a cholesterol-lowering drug and a contraceptive steroid to be effective in treating various cancers. The treatment, known as BaP, blocks an enzyme crucial to cancer cell growth and has shown promising results in early stage clinical trials.
Researchers at Cold Spring Harbor Laboratory have discovered the mechanism of action for BRD4, a protein critical to AML cell survival. Disrupting this pathway may lead to improved therapeutic strategies and new molecular targets for treating various cancers.
Researchers at Sandia National Laboratories and the University of Maryland have developed a new cancer treatment method that withholds an essential nutrient from cancer cells, starving them until they self-destruct. The method involves removing asparagine, a nutrient that cancer cells can't produce on their own.
A large study by Boston University School of Medicine researchers found no evidence of an association between Post Traumatic Stress Disorder (PTSD) and cancer incidence. This contradicts plausible theories suggesting a link between stress and cancer, but is consistent with previous population-based studies.
A drug developed in the late 1950s and abandoned due to toxicity has been revived as a treatment for advanced colorectal cancer. The drug, TAS-102, extended patients' overall survival and delayed disease progression with minimal side effects.
A Dartmouth team developed a novel approach for near infrared optical measurements of resected breast tissue using molecular dyes used for surgical specimen margin orientation. This method allows for intraoperative assessment during breast conserving surgery and avoids follow-up resections.
Researchers developed a unique approach using microscopic gas bubbles to deliver directly to cancer cells a viral gene therapy in combination with an experimental drug. The treatment strategy used a novel 'cancer terminator virus' and demonstrated enhanced prostate cancer cell death while sparing healthy cells in preclinical experiments.
Scientists at CSHL have developed a method to comprehensively identify binding pockets inside cancer cells that can be targeted by drugs. Using CRISPR, they surveyed about 200 potential targets and identified six known targets and 19 new ones in leukemia cells.
Researchers at Karolinska Institutet have discovered how cancer cells can infiltrate the lymphatic system by mimicking immune cells. This finding may lead to the development of new treatments targeting metastasis via the lymphatic system.
A study published in the Journal of Cell Biology suggests that new understanding of cell division can reveal potential targets for cancer therapy. Researchers have identified key steps in cell division and highlighted novel targets that could be inhibited to block cancer cell division.
Researchers developed a combinatorial approach to treating glioblastoma by combining three classes of anti-cancer drugs. The study found that a combination of EGFR inhibitor, PLK1 inhibitor and DNA-damaging agent effectively halted tumor growth in mouse models and human glioblastoma tissue.
Researchers used organoids derived from human tumor samples to test cancer drugs and predict patient response. The findings demonstrate the power of organoids to capture complex mutations in tumours.
Researchers grew 22 organoids from tumor tissue of 20 patients with colorectal cancer and found they closely replicate key properties of the original tumors. These cultures can be used to predict drug sensitivity and pave the way for personalized treatment approaches.
A phase I clinical trial has begun for a new 'resistance-busting' experimental skin cancer drug, administered to the first patient just three months after a major publication described its potential. The trial aims to establish the safe maximum dose for a planned phase II clinical trial, focusing on advanced melanoma patients.
Researchers have found a possible treatment for diffuse intrinsic pontine gliomas (DIPG), a lethal form of pediatric brain cancer. Panobinostat, an epigenetic drug, may slow DIPG growth and extend survival rates in patients.
Researchers at Dana-Farber Cancer Institute identified three types of resistance to a new lung cancer drug, highlighting the need for combination therapies and novel strategies to overcome resistance mechanisms.
A study by researchers at the University of Cincinnati has found that generic formulations of tacrolimus are bioequivalent to the name-brand version, suggesting they can be used interchangeably post-transplant. The findings have important implications for immunosuppressant drug management and patient care.
Researchers found that teens aged 15-17 who mixed energy drinks with alcohol were four times more likely to meet the criteria for alcohol use disorder. The study highlights the potential risks of combining these substances, particularly among adolescents.
A new targeted therapy drug rociletinib demonstrates significant activity against treatment-resistant EGFR-mutant lung tumors, improving outcomes for patients with advanced tumors. The drug showed promising results in patients with T790M-driven resistance, resulting in tumor shrinkage and symptom relief.
The pharmaceutical industry's regulatory system is criticized for lacking accountability and being evidence-based, resulting in high NHS costs and inefficient use of technology appraisal work. The Cancer Drugs Fund is also singled out for criticism due to its inequitable allocation of funds and discrimination against other diseases.
A phase 1/2 trial of rociletinib in EGFR-mutant non-small cell lung cancer showed a 59% response rate and 13.1 month progression-free survival, offering hope for patients with previously treated disease.
Chemists have designed four new atomic arrangements of gold nanoparticle clusters, exhibiting lower potential energy and greater stability than previous configurations. The arrangements could inform the use of these nanoparticles in transporting pharmaceutical drugs and removing pollutants from industrial byproducts.
A Mayo Clinic-led research team has identified a molecular switch in the HER2 protein that sets off a cascade of events leading to cancer. Disrupting this site can stem the growth of breast cancer cells more effectively than current treatments.
Scientists have identified 35 genes and three long intervening noncoding RNA molecules that spur aggressive activity in HER2+ breast cancer. These findings provide a new target for treatment approaches, potentially leading to RNA-based therapeutics.
Researchers identified specific molecular profiles and mutational patterns that can help determine which hepatocellular carcinoma patients benefit from targeted anticancer treatments. The study suggests that exome sequencing can be used to identify potential new targets for therapy, leading to optimized personalized patient care.
A Case Western Reserve University researcher has won a $500,000 NSF CAREER grant to develop tiny sensors capable of detecting insecticides in Lake Erie or determining subtypes of human cancers. The technology combines antibodies with plant viruses to create a large surface area for targeting pollutants or cancer cells.
A patented technology called CIVO enables simultaneous testing of multiple cancer drugs in a patient's tumor, accurately predicting systemic response. This innovation has shown positive findings using multiple cancer drugs tested in xenografted mouse models and canine patients.
A new implantable device can carry small doses of multiple drugs to treat cancer, allowing researchers to measure their effectiveness in a tumor. The device was tested on mice with human prostate, breast, and melanoma tumors, showing promise in identifying the most effective treatment for each patient.
Researchers found that a toxic mushroom-based drug can suppress the POLR2A gene in cancer cells, resulting in complete tumor regression and reduced toxicity. The study's findings provide a new therapeutic approach for human cancers with common genomic alterations.
A Purdue University study reveals that cancer drug decitabine combats cell damage by taking the place of nucleotide cytosine, restoring 'meaning' to garbled gene messages. An uptick in 5-hydroxymethylcytosine levels could indicate cancer treatment success.
A major trial has shown that olaparib can effectively treat advanced prostate cancer in men with defects in DNA repair genes. The results suggest that up to 30% of patients with terminal prostate cancer may benefit from the drug, which could become a treatment option if replication is confirmed in further trials.
Researchers have tested an experimental immune system drug, MPDL3280A, in a preliminary human study and found it to be generally safe and well-tolerated. The therapy aims to restore the immune system's ability to recognize and attack cancer cells, with promising results in controlling disease in some patients.
Researchers have identified a new mechanism linking chronic inflammation to cancer progression, revealing the role of MUC1 and p65 in driving pro-inflammatory cytokine gene expression. This discovery offers potential therapeutic targets for developing drugs that can interrupt the cancer-inflammation process.
A new report from UC San Diego highlights the scope of the problem, finding that only 1,510 counterfeit incidents were reported between 2009 and 2011, despite an estimated 100,000-1 million deaths per year. The study calls for improved detection, data collection, and analysis to combat falsified medicines.
A gene expression model called COXEN predicts canine osteosarcoma response to doxorubicin, potentially allowing veterinary oncologists to choose the most effective drug. The approach validates human models used to predict drug response in clinical trials.
A new study from the University of Pennsylvania School of Medicine found that pembrolizumab, a PD-1 inhibitor, shrank or stabilized tumors in most patients with pleural mesothelioma. The medication was safe and showed promise for treating this rare and deadly form of cancer.
Researchers at MD Anderson Cancer Center identified three subsets of lung cancer with KRAS gene mutations, each with unique signaling patterns and susceptibility to different therapeutic strategies. These subsets may offer new approaches for treating lung adenocarcinoma, the most common form of lung cancer.
Researchers at Saint Louis University discovered that targeting the A3 adenosine receptor can 'turn off' pain signals in the spinal cord, providing potential relief for patients with chronic pain. The study found that activating this receptor promotes GABA signaling, which is often lost or diminished in chronic pain conditions.
A common anti-fungal drug, itraconazole, has shown potential in treating metastatic prostate cancer and non-small cell lung cancer. The ReDO project is exploring its use in various cancers, offering a more affordable alternative to existing treatments.
A new clinical trial found that early initiation of palliative care significantly improved one-year survival rates among patients with late-stage cancer. Additionally, caregivers experienced reduced depression and stress levels when interventions started earlier in the patient's life.
A multicenter clinical trial launched by Yale University aims to evaluate the effectiveness of personalized medicine in treating metastatic melanoma. The trial will enroll patients lacking a particular genetic mutation and use molecular sequencing techniques to match targeted drugs to unique genetic alterations.
A recent study published in Science Translational Medicine found that many genetic alterations identified using tumor-only sequencing are not associated with cancer, but rather reflect inherited germline mutations. The study analyzed DNA from 815 patients and found that nearly half of the detected genetic alterations were 'false positi...
Dartmouth researchers have identified a specific temperature that stimulates an antitumor immune response, which resists metastatic disease. Using iron nanoparticles and alternating magnetic fields, they found that temperatures of 43 degrees centigrade trigger the systemic immune response.
Scientists at MIT created a new cancer therapy that activates both the innate and adaptive immune systems to attack tumors. The treatment combines an antibody drug with IL-2, which boosts immune responses, resulting in complete tumor disappearance in 80-90% of mice.
Researchers at Queen's University Belfast have launched a revolutionary personalized treatment program to improve bowel cancer survival rates. The S-CORT Consortium will employ state-of-the-art techniques to define the genetic make-up of bowel cancer cells, collected from over 2,000 patients, and develop personalized care plans.
Recent studies in Cancer Cell and Trends in Immunology review the intricate relationship between the immune system and cancer. Research has shown that harnessing anti-tumor immunity can be a promising approach to treating various cancers.
Researchers discovered a previously invisible biological process that may be implicated in the rapid growth of some cancers. The new study reveals that a well-known cancer protein called mTOR can hand off its work to another protein, CDK1, when cells are dividing.
Moffitt scientists developed a novel technique to analyze the MDMX protein, revealing its auto-inhibitory segment that controls p53 activity. This discovery may help identify patients more likely to respond to an MDMX-targeted cancer drug.
A research team has identified a drug target for ATRA, a treatment for acute promyelocytic leukemia (APL), by targeting the Pin1 enzyme. The discovery offers a promising new way to fight aggressive or drug-resistant cancers by degrading cancer stem cells and blocking multiple cancer-driving pathways.
Scientists at the University of Southampton have developed a drug that can reverse resistance to immunotherapy in certain leukaemias and non-Hodgkin lymphomas. The new antibody, BI-1206, works by binding to a molecule called FcγRIIB and enhancing cancer killing, promising improved treatment outcomes for patients with blood cancers.
Researchers James P. Allison and Padmanee Sharma argue that combining targeted therapies with immunotherapy could be key to developing curative treatments for various cancer types, building on promising results from clinical trials.
Researchers at Scripps Research Institute have received a grant to investigate the Hippo-YAP signaling pathway in various cancers, including breast and colorectal cancer. The study aims to identify compounds targeting this pathway to combat cancer, with a focus on ultra-high-throughput screening resources.
Researchers at the University of Texas MD Anderson Cancer Center review the potential of combining genomically targeted therapies with immune checkpoint blockade drugs to attack cancer. The approach shows promise, but more support is needed to accelerate progress and minimize side effects.
Researchers have identified six chemical compounds that inhibit HuR, a protein promoting tumor growth. The findings hold promise for treating various cancers and could lead to a novel class of cancer therapies.